Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.

IgG monoclonal antibodies (mAbs) consist of two Fab fragments and one Fc fragment. The Fab fragments contain the variable regions and are responsible for drug specificity (via antigen binding); the Fc fragment contains constant regions and is responsible for effector functions (via interactions with Fcγ receptors) and extended serum half-life (via interaction with the neonatal Fc receptor, FcRn). There are two conserved methionine (Met) residues located in the FcRn binding site of the Fc fragment. It has been shown previously that oxidation of these two Met residues decreases the binding affinity to FcRn. We have further evaluated the impact of Met oxidation on serum half-lives of two humanized IgG1 mAbs in transgenic mice with human FcRn. Variable oxidation levels were obtained by several procedures: exposure to an oxidizing agent, accumulation during extended refrigerated storage, or chromatographic separation. Our results show that Met oxidation can result in a significant reduction of the serum circulation half-life and the magnitude of the change correlates well with the extent of Met oxidation and changes in FcRn binding affinities. The relatively low levels of Met oxidation accumulated during 3 years of refrigerated storage had minimal impact on FcRn binding and no detectable impact on the serum half-life.

[1]  R. Ober,et al.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.

[2]  Kinetics of chemical degradation in monoclonal antibodies: relationship between rates at the molecular and peptide levels. , 2010, Analytical chemistry.

[3]  Bruce Tidor,et al.  Quantitative methods for developing Fc mutants with extended half-lives. , 2005, Biotechnology and bioengineering.

[4]  D. Brems,et al.  Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics. , 2007, Biochemistry.

[5]  E. Ward,et al.  Multiple roles for the major histocompatibility complex class I- related receptor FcRn. , 2000, Annual review of immunology.

[6]  Huub Schellekens,et al.  Immunological mechanism underlying the immune response to recombinant human protein therapeutics. , 2010, Trends in pharmacological sciences.

[7]  Reed J. Harris,et al.  The application of tert-butylhydroperoxide oxidation to study sites of potential methionine oxidation in a recombinant antibody , 1996 .

[8]  Gang Huang,et al.  Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn , 2009, Protein science : a publication of the Protein Society.

[9]  G. A. Lazar,et al.  Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.

[10]  Rao Pe,et al.  Orthoclone OKT3. Chemical mechanisms and functional effects of degradation of a therapeutic monoclonal antibody. , 1993 .

[11]  Hongcheng Liu,et al.  Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody , 2009, Journal of the American Society for Mass Spectrometry.

[12]  Da Ren,et al.  Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. , 2008, Biochemistry.

[13]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[14]  R. Ionescu,et al.  Separation of post-translational modifications in monoclonal antibodies by exploiting subtle conformational changes under mildly acidic conditions. , 2010, Journal of chromatography. A.

[15]  Tetsu Kobayashi,et al.  Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.

[16]  Marie-Paule Lefranc,et al.  Human immunoglobulin allotypes , 2009, mAbs.

[17]  N. Tsurushita,et al.  An Engineered Human IgG1 Antibody with Longer Serum Half-Life , 2006, The Journal of Immunology.

[18]  Thomayant Prueksaritanont,et al.  Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. , 2009, Molecular immunology.

[19]  A. West,et al.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. , 2001, Molecular cell.

[20]  Hongcheng Liu,et al.  Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[21]  P. Bjorkman,et al.  Effects of receptor dimerization on the interaction between the class I major histocompatibility complex-related Fc receptor and IgG. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Leonard G Presta,et al.  Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. , 2006, International immunology.

[23]  J L Cleland,et al.  Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. , 1997, Journal of pharmaceutical sciences.

[24]  Leonard G Presta,et al.  Molecular engineering and design of therapeutic antibodies. , 2008, Current opinion in immunology.

[25]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[26]  Hui Zhao,et al.  Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. , 2009, Journal of pharmaceutical sciences.

[27]  Hongcheng Liu,et al.  Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. , 2008, Molecular immunology.

[28]  R. Keck.  The use of t-butyl hydroperoxide as a probe for methionine oxidation in proteins. , 1996, Analytical biochemistry.

[29]  Damian Houde,et al.  Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.